Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Alnylam
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Alnylam
-
We’re pleased to announce that we’ve received a positive opinion from the EMA (
@EMA_News) Committee for Medicinal Products for Human Use (#CHMP) for our investigational#RNAi therapeutic for the treatment of the#raredisease acute hepatic#porphyria.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Acute hepatic
#porphyria (AHP) refers to a family of rare, often misdiagnosed genetic diseases characterized by potentially life-threatening attacks and, for some patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life.#rarediseaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alnylam proslijedio/la je Tweet
Thanks
@BostonGlobe and@damiangarde for highlighting the@Alnylam story as one of the successes in the Boston/Cambridge ecosystem! There is no better place in the world to make a medicine than right here!https://www.bostonglobe.com/2020/01/28/opinion/if-you-want-develop-new-medicine-boston-is-place/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Symptoms of acute hepatic
#porphyria (AHP) can often lead to misdiagnoses of more common conditions such as IBS, fibromyalgia, appendicitis & endometriosis. As a result, patients often remain w/o a proper diagnosis for up to 15 yrs.#rarediseaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alnylam proslijedio/la je Tweet
What a week! Thank you partners and sponsors for supporting
#2020RITS and#raredisease.@tradegovukUSA@Alnylam@GileadSciences@HorizonNews@Cydanco@genentech@Insmed@IpsenGroup@RetrophinRare@VertexPharma@AlexionPharma@MDAorg@demycolton@EBDgroup#CareAboutRarepic.twitter.com/99Tr0vGd4A
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're
#AlnylamProud to welcome our first Co-op class of the new decade! This outstanding group of 33 co-ops and legal externs represents@Northeastern,@UMassAmherst and@BU_Law. Learn more about career development at Alnylam here: http://bit.ly/2Li20kD pic.twitter.com/Pb3cjRBjyK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PH1 of a Kind is a 4-part video series for kids, about kids from around the world who have been diagnosed with primary hyperoxaluria type 1 (PH1). The videos star Isabelle, Luuk, Asha and Will and each tackles a different challenge they face living with this
#raredisease.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This afternoon, we announced preliminary Q4 and full year 2019 global net product revenues and additional updates. Tune in to our live
#JPM20 webcast tomorrow at 1:30 PM ET/10:30 AM PT to learn more. Access the webcast here: http://bit.ly/2R0JobXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're pleased to announce today that we've initiated a rolling submission of a New Drug Application (NDA) to the
@US_FDA for lumasiran, an investigational#RNAi therapeutic for the treatment of primary#hyperoxaluria type 1 (PH1).#rarediseaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Peggy’s life partner Dan, who is living with
#hATTR#amyloidosis, inspired her to convey the puzzling challenges of the disease through an original artwork as part of the “The Art of Living with hATTR Amyloidosis” project. They discuss their story in a new Q&A.#rarediseaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
People who may have the
#raredisease primary#hyperoxaluria type 1 can talk to their doctor about Alnylam Act’s no-cost, 3rd-party genetic testing & counseling. Alnylam Act may help accelerate or confirm a PH1 diagnosis so families can make informed decisions about their health.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New year! New role? We've got >150 open roles in the US, Europe and Asia including many in research, clinical development, clinical operations, quality, medical affairs and manufacturing. Perhaps this is YOUR moment to join a leader that is also a recognized top employer.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alnylam proslijedio/la je Tweet
Thrilled to see the arrival of gene silencing medicines (our
#RNAi therapeutics) included in this great recap of important breakthroughs in medical science in 2019 by@BBCNews!https://www.bbc.com/news/health-50813226 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“Living a Rare Life” is the story of one family’s journey to unlock the mysteries of a life-threatening genetic
#raredisease called#hATTR#amyloidosis and how examining their health history across generations proved to be critical.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
As we enter the new decade, we look forward to seeing the incredible biomedical breakthroughs from our industry to come and look back with pride on our contribution to the innovations of the past decade. And
#RNAi is just getting started!#biotech#rarediseaseHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Supporting patient access to innovative treatments is at the core of our Patient Access Philosophy and our head of Patient Services discusses how her team works with patients in many ways to help them navigate the evolving complexities of today’s healthcare system in a new Q&A.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
For many people, like CeCe, it can take years to be accurately diagnosed with
#hATTR amyloidosis. Click the link below to learn more about CeCe’s story, the signs and symptoms of this#raredisease and the importance of having meaningful conversations with your doctor.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats to our CEO
@JMaraganore on being voted the 2019@statnews best#biotech CEO. His passion for our science and unwavering commitment to helping people living with disease motivates and inspires us every day...and has since 2002!#RNAi#leadershiphttp://bit.ly/2Sbx6zPHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alnylam proslijedio/la je Tweet
Don't miss this Interview with the 2019 OTS Lifetime Achievement Award Winner Muthiah (Mano) Manoharan!
$ALNY$ARWR$DRNA$ABUS$SLN$AMGN@OliXPharmaceut1#siRNA#RNAi@RNAi_papers@JMaraganore@Alnylam@ArrowheadPharma@SilenceTheraPlc@DicernaPharma https://www.oligotherapeutics.org/interview-with-mano-manoharan/ …pic.twitter.com/kZiUORnT8m
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.